Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Falls Church, Virginia Clinical Trials

A listing of Falls Church, Virginia clinical trials actively recruiting patient volunteers.

RESULTS

Found (206) clinical trials

MGD009/MGA012 Combination in Relapsed/Refractory Cancer

This study is a Phase 1, open-label, dose escalation, and cohort expansion study designed to characterize the safety, tolerability, PK, pharmacodynamics, immunogenicity, and preliminary antitumor activity of the combination of MGD009 and MGA012, each of which is administered by IV infusion.The study consists of a Dose Escalation Phase to determine ...

Phase

5.27 miles

Learn More »

First-in-human Study of DS-1062a for Advanced Solid Tumors

The dosage strength will change during the study but all participants will receive the same study drug. So the study is not a true 2-arm study, it is a 2-part study. In both parts, subjects with pathologically documented unresectable advanced NSCLC who have been refractory to or relapsed from standard ...

Phase

5.27 miles

Learn More »

Study of STRO-001 an Anti-CD74 Antibody Drug Conjugate in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who ...

Phase

5.27 miles

Learn More »

PF-06821497 Treatment Of Relapsed/Refractory SCLC Castration Resistant Prostate Cancer and Follicular Lymphoma

This is an open label, multi center, Phase 1 dose escalation study of PF 06821497 administered orally as a single agent BID to patients with SCLC, CRPC, DLBCL and FL (Part 1A). For Part 1B (dose escalation monotherapy), PF 06821497 will be administered as monotherapy in patients with FL. For ...

Phase

5.27 miles

Learn More »

MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation trial with consecutive parallel-group expansion in selected solid tumor indications. The current trial is composed of a standard dose escalation "3 + 3" cohort design, for which 3 to 6 subjects will be enrolled at each dose level depending on the occurrence of ...

Phase

5.27 miles

Learn More »

A Phase I Study of Safety Tolerability and PK of AZD2811 in Patients With Advanced Solid Tumors.

This is a first-time-in-patient (FTIP) study with the nanoparticle formulation of AZD2811 primarily designed to evaluate the safety and tolerability of AZD2811 at increasing doses in patients with advanced solid tumours and for whom no standard of care exists. The study will be conducted in two parts: Part A dose-escalation ...

Phase

5.27 miles

Learn More »

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Determine the safety, tolerability, dose limiting toxicities (DLTs), and maximum tolerated dose (MTD) of ACY 241 in combination with nivolumab.

Phase

5.27 miles

Learn More »

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

This is a phase 1a / 1b, first-in-human, open-label, dose-escalation, safety, pharmacokinetics, and pharmacodynamic study of TP-0903 administered once daily for the first 21 out of 28 days. There are 2 phases in this study. In Phase 1a (dose escalation), sequential cohorts of three (3) patients will be treated with ...

Phase

5.27 miles

Learn More »

A Phase 1 Study of TSR-022 an Anti-TIM-3 Monoclonal Antibody in Patients With Advanced Solid Tumors (AMBER)

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Phase

5.27 miles

Learn More »